CytomX Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $25.5M | $188.4M |
| FY2020 | — | $-7.8M | $191.9M |
| FY2021 | — | $80.7M | $205.5M |
| FY2022 | — | $-29.7M | $193.7M |
| FY2023 | — | $-47.4M | $17.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $25.5M | $188.4M |
| FY2020 | — | $-7.8M | $191.9M |
| FY2021 | — | $80.7M | $205.5M |
| FY2022 | — | $-29.7M | $193.7M |
| FY2023 | — | $-47.4M | $17.2M |